Related Experiment Video
Updated: Jul 19, 2026

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
Vaccine manufacturing: challenges and solutions
Jeffrey B Ulmer1, Ulrich Valley, Rino Rappuoli
1Novartis Vaccines and Diagnostics, 4560 Horton St., Mailstop 4.3, Emeryville, California 94608, USA. jeffrey_ulmer@chiron.com
Abstract:
The recent influenza vaccine shortages have provided a timely reminder of the tenuous nature of the world's vaccine supply and the potential for manufacturing issues to severely disrupt vital access to important vaccines. The application of new technologies to the discovery, assessment, development and production of vaccines has the potential to prevent such occurrences and enable the introduction of new vaccines. Gene-based vaccines, virus-like particles, plant-derived vaccines and novel adjuvants and delivery systems represent promising approaches to creating safer, more potent vaccines. As a consequence, more people will have faster access to more effective vaccines against a broader spectrum of infectious diseases. However, the increased cost of producing new vaccines and regulatory uncertainty remain challenges for vaccine manufacturers.
Related Concept Videos
Vaccine Production
Vaccinations
Microorganisms in Medicine and Therapeutics
Vaccines
Production of Pharmaceuticals
Upstream Processing

